20/20 Biolabs, Inc. (AIDX)Healthcare | Medical Devices | Gaithersburg, United States | NasdaqCM
0.57 USD
-0.02
(-3.276%) ⇩
(July 13, 2026, 4 p.m.
EDT)
After hours: 0.56 -0.01 (-0.007%) ⇩ (July 13, 2026, 7:50 p.m. EDT) |
Hot Take ↕ | July 11, 2026, 5:26 a.m. EDT
The investment case for this biotech firm is currently broken by a catastrophic collapse in business fundamentals. Revenue has contracted by 36% year-over-year, while the company burns significant cash with negative operating and free cash flows, resulting in severe losses on both assets and equity. The balance sheet is fragile, with debt-to-equity exceeding 33%, and the stock trades at a premium to book value despite generating no profit. While the company recently transitioned to Nasdaq and received index inclusion, these events cannot mask the reality that the core business is shrinking rapidly. The recent price action shows the stock hovering near its 52-week low, confirming that the market has already priced in this deterioration. With no dividend to provide income and a trajectory of declining sales and profitability, there is no rational basis for a long-term hold or a short-term trade given the very low confidence in any statistical price forecasts. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.205277 |
| MSTL | 0.526857 |
| AutoETS | 0.549134 |
| AutoARIMA | 0.769215 |
Forecast horizon: 60 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 26% |
| H-stat | 20.30 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.044 |
| Excess Kurtosis | -1.44 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 33.567 |
| Revenue per Share | 0.327 |
| Market Cap | 6,980,733 |
| Profit Margins | -279.13% |
| Previous Name | 20/20 GeneSystems Inc. |
| Website | https://2020biolabs.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.97526205 |
| Address1 | 15,810 Gaither Road |
| Address2 | Suite 235 |
| All Time High | 50.0 |
| All Time Low | 0.51 |
| Ask | 1.0 |
| Ask Size | 1 |
| Average Daily Volume10 Day | 365,900 |
| Average Daily Volume3 Month | 793,827 |
| Average Volume | 793,827 |
| Average Volume10Days | 365,900 |
| Bid | 0.61 |
| Bid Size | 1 |
| Book Value | 0.244 |
| City | Gaithersburg |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 0.5698 |
| Current Ratio | 1.822 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 0.6 |
| Day Low | 0.561 |
| Debt To Equity | 33.567 |
| Display Name | 20/20 Biolabs |
| Ebitda | -3,921,809 |
| Ebitda Margins | -2.1260002 |
| Enterprise To Ebitda | -0.754 |
| Enterprise To Revenue | 1.603 |
| Enterprise Value | 2,957,075 |
| Eps Trailing Twelve Months | -0.49 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 0.9672 |
| Fifty Day Average Change | -0.39739996 |
| Fifty Day Average Change Percent | -0.41087672 |
| Fifty Two Week Change Percent | -97.52621 |
| Fifty Two Week High | 50.0 |
| Fifty Two Week High Change | -49.4302 |
| Fifty Two Week High Change Percent | -0.98860395 |
| Fifty Two Week Low | 0.51 |
| Fifty Two Week Low Change | 0.05980003 |
| Fifty Two Week Low Change Percent | 0.11725496 |
| Fifty Two Week Range | 0.51 - 50.0 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,771,511,400,000 |
| Float Shares | 8,688,507 |
| Free Cashflow | -1,301,893 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 4 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.27193 |
| Gross Profits | 501,630 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.26158002 |
| Held Percent Institutions | 0.02496 |
| Implied Shares Outstanding | 12,251,198 |
| Industry | Medical Devices |
| Industry Disp | Medical Devices |
| Industry Key | medical-devices |
| Ipo Expected Date | 2,026-02-19 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | 20/20 Biolabs, Inc. develops and commercializes AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. It provides OneTest for Cancer, a multi-cancer early detection, or MCED and OneTest for Longevity, which measures inflammatory biomarkers. It also operates the Clinical Lab Innovation Axcelerator (CLIAx), a CLIA laboratory for overseas diagnostics start-ups. The company was formerly known as 20/20 GeneSystems, Inc. and changed its name to 20/20 Biolabs, Inc. in March 2025. The company was incorporated in 2000 and is based in Gaithersburg, Maryland. |
| Long Name | 20/20 Biolabs, Inc. |
| Market | us_market |
| Market Cap | 6,980,733 |
| Market State | POSTPOST |
| Max Age | 86,400 |
| Message Board Id | finmb_7685164 |
| Most Recent Quarter | 1,774,915,200 |
| Name Change Date | 2,026-07-13 |
| Net Income To Common | -5,094,888 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 7,217,425 |
| Number Of Analyst Opinions | 1 |
| Open | 0.5877 |
| Operating Cashflow | -2,720,387 |
| Operating Margins | -4.08449 |
| Payout Ratio | 0.0 |
| Phone | (240) 453-6339 |
| Post Market Change | -0.006799996 |
| Post Market Change Percent | -1.1934004 |
| Post Market Price | 0.563 |
| Post Market Time | 1,783,986,649 |
| Prev Name | 20/20 GeneSystems Inc. |
| Previous Close | 0.5891 |
| Price Hint | 4 |
| Price To Book | 2.3352458 |
| Price To Sales Trailing12 Months | 3.784235 |
| Profit Margins | -2.7913 |
| Quick Ratio | 1.713 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.0193 |
| Regular Market Change Percent | -3.27618 |
| Regular Market Day High | 0.6 |
| Regular Market Day Low | 0.561 |
| Regular Market Day Range | 0.561 - 0.6 |
| Regular Market Open | 0.5877 |
| Regular Market Previous Close | 0.5891 |
| Regular Market Price | 0.5698 |
| Regular Market Time | 1,783,972,801 |
| Regular Market Volume | 158,875 |
| Return On Assets | -0.58853 |
| Return On Equity | -2.41593 |
| Revenue Growth | -0.362 |
| Revenue Per Share | 0.327 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 12,251,198 |
| Shares Percent Shares Out | 0.0153 |
| Shares Short | 186,863 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 128,775 |
| Short Name | 20/20 Biolabs, Inc. |
| Short Percent Of Float | 0.0184 |
| Short Ratio | 0.11 |
| Source Interval | 15 |
| State | MD |
| Symbol | AIDX |
| Target High Price | 5.0 |
| Target Low Price | 5.0 |
| Target Mean Price | 5.0 |
| Target Median Price | 5.0 |
| Total Cash | 4,219,099 |
| Total Cash Per Share | 0.398 |
| Total Debt | 925,487 |
| Total Revenue | 1,844,688 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.49 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 2.0862246 |
| Two Hundred Day Average Change | -1.5164245 |
| Two Hundred Day Average Change Percent | -0.726875 |
| Type Disp | Equity |
| Volume | 158,875 |
| Website | https://2020biolabs.com |
| Zip | 20,877 |